To better understand the cellular origin of breast cancer, we developed a mouse model that recapitulates expression of the ETV6-NTRK3 (EN) fusion oncoprotein, the product of the t(12;15)(p13;q25) translocation characteristic of human secretory breast carcinoma. Activation of EN expression in mammary tissues by Wap-Cre leads to fully penetrant, multifocal malignant breast cancer with short latency. We provide genetic evidence that, in nulliparous Wap-Cre;EN females, committed alveolar bipotent or CD61 + luminal progenitors are targets of tumorigenesis. Furthermore, EN transforms these otherwise transient progenitors through activation of the AP1 complex. Given the increasing relevance of chromosomal translocations in epithelial cancers, such mice serve as a paradigm for the study of their genetic pathogenesis and cellular origins, and generation of preclinical models.
INTRODUCTION
For most malignancies neither the initiating genetic event nor the cell of origin is known. Cancers are heterogeneous in composition and are organized in a hierarchy that includes cells competent to recreate the tumor on transplantation, designated tumor initiating cells (T-ICs) or cancer stem cells, and other cells comprising the bulk tumor mass (Reya et al., 2001) . Following the first hit, whether it occurs within a stem or more differentiated cell, secondary events of genetic or epigenetic nature contribute to evolution of malignancy. Access to these early steps in
SIGNIFICANCE
For the largest class of human tumors, those of epithelial origin, little is known about their initiating genetic hits or cells of origin. Whether tissue stem cells or more committed progenitors are targets for transformation is uncertain. We developed a system in which epithelial tumorigenesis can be assessed from the initial event to frank malignancy. In this breast cancer model based on chromosomal translocation, we show through genetic marking that committed mammary progenitors, rather than mammary stem cells, are direct targets of transformation. We show that activation of the AP1 complex represents a critical downstream event of the ETV6-NTRK3 translocation. Further focus on this transcriptional complex as a target in human breast cancer is warranted.
cancer formation is impossible in patients. Animal models provide a window into this phase of cancer development but are likely to be relevant to human biology only so far as the genetic events mirror those occurring in patients.
In considering these issues, we have sought to apply to a cancer of epithelial origin principles that have proved successful in the study of hematopoietic malignancies. For leukemias and childhood sarcomas, chromosomal translocations leading to the production of chimeric proteins serve as initiating genetic events (Rowley, 2001) . Although some gene rearrangements associated with leukemia are rare, study of these infrequent events has defined transcription factors critical for normal differentiation and pathways more generally perturbed in malignancy.
Until lately, the contribution of chromosomal rearrangements to epithelial cancers has been viewed as minor. Recently, chromosomal rearrangements involving the ETS family transcription factors were identified in >50% cases of human prostate cancer (Tomlins et al., 2005 (Tomlins et al., , 2006 (Tomlins et al., , 2007 . Furthermore, an EML4-ALK fusion gene was identified in 6.7% of non-small-cell lung cancer cases (Soda et al., 2007) . These observations prompt reassessment of conclusions regarding the involvement of chromosomal rearrangements in epithelial cancer.
t(12;15)(p13;q25) is a unique recurrent chromosomal translocation associated with cancer of all germ layers, including human secretory breast carcinoma (SBC) (Tognon et al., 2002) , congenital fibrosarcoma (Knezevich et al., 1998b) , congenital mesoblastic nephroma (Knezevich et al., 1998a; Rubin et al., 1998) , and acute myelogenous leukemia (Eguchi et al., 1999) . It produces a fusion oncogene, ETV6-NTRK3 (EN), which encodes a chimeric protein made up of the oligomerization domain of ETV6 (also known as TEL, an ETS family transcription factor) and the protein tyrosine kinase (PTK) domain of NTRK3 (also known as TRKC, a TRK family tyrosine kinase receptor for neurotrophin-3). The consistent presence of this translocation in human SBC provides strong genetic epidemiological support for its role in the initiation of breast cancer (Tognon et al., 2002) .
Breast cancer is representative of other epithelial malignancies in its heterogeneity, both genetically and clinically (Simpson et al., 2005) . In part, phenotypic heterogeneity may reflect diverse cellular origins of different subtypes of breast cancer (Ince et al., 2007) .
Here we report a murine model of human sporadic breast cancer based on the EN translocation. We demonstrate that two committed mammary progenitors in the normal mammary developmental hierarchy serve as target cells of breast cancer. In addition, by performing microarray analysis, we reveal that EN-initiated transformation is mediated largely through activation of the c-Jun/Fosl1 AP1 complex.
RESULTS

Generating the Etv6-NTRK3 Conditional Knockin Allele
We generated a Cre-Lox EN knockin allele by introducing the portion of human NTRK3 cDNA encoding the PTK domain (as found in SBC patients) into exon 6 of the mouse Etv6 locus ( Figure 1A ). We rendered this fusion allele conditional by insertion of a ''floxed'' transcriptional terminator sequence (''stopper'' [Mao et al., 1999] ; Figure 1A ] into the intron upstream of the knockin NTRK3 cDNA. The resulting allele, once activated by Cre-mediated excision of the floxed ''stopper,'' produces a mouse Etv6-human NTRK3 hybrid protein, which transforms NIH 3T3 cells (data not shown). Therefore, the EN knockin allele recapitulates the chimeric protein seen in patients.
We identified correctly targeted ES cell clones using Southern blot ( Figure 1B) . By RT-PCR, we found EN ES cells without excision exhibited slightly leaky expression of the EN allele, but removal of the ''stopper'' greatly increased its expression ( Figure 1C) . At the protein level ( Figure 1D ), no EN fusion protein was detected in unexcised ES cells. However, its expression was readily visible from ''stopper''-excised ES cells. Thus, the EN conditional knockin allele functions as designed.
The Endogenous Etv6 Locus Is Active in Mammary Epithelial Cells
Because EN is under the control of the endogenous Etv6 promoter, we first examined where Etv6 is normally expressed in mammary glands (MGs) using a mouse strain we generated (TEA175) that carries an Etv6 locus having a b-Geo cassette inserted between its exons 2 and 3 and serves as a reporter for its expression.
Upon staining MGs from TEA175 heterozygous females for lacZ activity, we found that Etv6 is expressed in both ductal and alveolar mammary epithelial cells (MECs) (Figure S1A in the Supplemental Data available with this article online). In addition, flow cytometry analysis revealed lacZ + cells in all four major MEC subpopulations defined previously ( Figure S1B ). Figure 1C ). To activate EN expression in MGs, we initially planned to use two commonly used MG-specific Cre mouse lines, MMTV-Cre and Wap-Cre (Wagner et al., 1997) . Unfortunately, use of MMTV-Cre led to a lethal myeloproliferative disease within several weeks after birth, apparently due to expression of MMTV-Cre in the hematopoietic system (data not shown).
Activation of EN in Mammary Glands by
The more restricted expression of the endogenous Wap gene as well as that of the Wap-Cre transgene (Boulanger et al., 2005; Kordon et al., 1995; Robinson et al., 1995 Robinson et al., , 1996 Wagner et al., 2002) Figure 2A) , with preceding lobuloalveolar hyperplasia ( Figure 2B ). Parous WCEN females develop similar multifocal mammary tumors with antecedent alveolar hyperplasia, and with no significant differences in tumor latency and histology. Some aged WCEN males also develop mammary tumors ( Figure 2A and data not shown).
To confirm that mammary tumors in WCEN animals resulted from activation of EN expression, we performed PCR analysis on genomic DNA prepared from tumors and other organs of WCEN animals and found that the ''stopper'' in the EN allele was excised only in tumor cells ( Figure 2C ). Consistent with this, we also detected EN protein in tumor tissues by western blot ( Figure 2D) . Previous studies demonstrated that expression of the EN fusion protein in 3T3 cells led to constitutive phosphorylation of Mek1/2 and Akt as well as to a constitutive highlevel expression of cyclin D1/2 (Tognon et al., 2001) . These features also characterized EN-initiated mammary tumors (hereafter, EN tumors) ( Figure 2D ). EN tumors were heterogeneous both with respect to morphology and rate of tumor progression (Figures 2Ea-2Ed and data not shown). Most EN tumors were highly invasive and transplantable upon subcutaneous injection into immunodeficient mice. The rate of tumor regrowth following transplantation correlated with the apparent rate of progression of the corresponding primary tumor. Due to the relatively short latency of these tumors, most WCEN mice failed to show signs of metastasis. On occasion, metastases to lymph node and lung were observed (Figures 2Ef and 2Eh) . (Kordon et al., 1995; Robinson et al., 1995 Robinson et al., , 1996 Figure 3A ). To test this hypothesis, we interbred a Rosa-Stop-lacZ reporter (Mao et al., 1999) Stingl et al., 2006; Welm et al., 2002) . By flow cytometry analysis, most EN tumor cells were CD24 + Sca-1 + ( Figure 3F ). Figure 3F ). These data argue that mammary tumors in WCEN mice are unlikely to arise from transformation of MaSCs; instead, they may be derived from committed CD24 + Sca-1 + mammary progenitors.
Wap-Cre;EN Mammary Tumors Are Derived from Committed Alveolar Progenitors
In analogy to the hematopoietic system, a developmental hierarchy for MECs, including MaSCs, bipotent ductal or alveolar progenitors, single lineage-restricted progenitors, and mature luminal or myoepithelial cells, has been proposed (Asselin-Labat et al., 2007; Hennighausen and Robinson, 2005) . To position target cells of EN in this hierarchy, we performed immunostaining for the luminal epithelial cell marker keratin 8 (K8), basal/myoepithelial cell markers keratin 5 (K5) and 14 (K14), p63, and a-smooth muscle actin (SMA), as well as the mammary progenitor marker keratin 6 (K6), and estrogen receptor (ERa) ( Figure 4A and Figure S2 ). Overall, we have identified two broad tumor types in WCEN mice. Figure S5 ). Gene names for each cluster are listed in Table S8 . In the heat map, red, black, and green represent above average, average, and below average levels of expression, respectively. Gray indicates no data recorded.
( Figure 4A and Figure S2A ). Figure S2A ), thus representing tumors with features of both types (1 and 2). A summary of the staining properties of cells in the different types of EN tumors is provided in Figure S2B . The majority of type 1 tumors contain K6-expressing cells, whereas very few or no K6
+ cells are present in type 2 tumors ( Figure S2C ). However, tumors of both types express Sca-1 (data not shown) and are ERa + ( Figure S2E ). Figure 4B ). We also detected a small population of K8 + K14 + cells, a significant number of which also express CD61 ( Figure 4B ). These data suggest that CD61 À mature luminal epithelial cells.
In type 1 EN tumors, the K5 + basal/myoepithelial cells, in addition to the K8 + luminal cells, are part of the tumor epithelial cell population. When we compared microarray expression profiles generated from sorted tumor epithelial cells based on the above-described lacZ marker in WCENLZ females to those from unfractionated tumors, we observed slight enrichment (rather than loss) of both the K5 basal gene cluster and the K14 cluster (as defined in Figure 4C , discussed below) in sorted lacZ + tumor cells, as determined by gene set enrichment assay (GSEA) (data not shown) (Subramanian et al., 2005) . This confirms that basal/myoepithelial cells in EN tumors are part of the tumor epithelial cells, not normal cells recruited to tumors. Due to the presence of mixed cell types in type 1 EN tumors, the cells from which tumors originate could be MaSCs, bipotent progenitors, or multiple lineagecommitted progenitors. Since the above-described genetic marking experiment and flow cytometry analysis (Figure 3 ) both rule out MaSCs as targets of EN, we next asked whether tumors are derived from distinct lineagerestricted progenitors (i.e., multiclonal), or from bipotent progenitors (i.e., clonal).
We used a Wap-rtTA-Cre transgenic line that expressed Cre in Wap + cells in the presence of doxycycline (Utomo et al., 1999) . We generated animals with both Wap-rtTACre and EN, some of which also carried a conditional luciferase reporter at the Rosa26 locus (Rosa-Stop-Luc, similar to the above-described Rosa-Stop-lacZ reporter [Safran et al., 2003] Figure S3B ). Since it is highly unlikely for multiple lineage-restricted progenitors to obtain the same partial excision pattern (as described above) and then give rise to a tumor with this pattern, our observation supports the clonal origin of type 1 EN tumors from bipotent progenitors. Furthermore, microarray data reveal that, compared to normal MGs, both type 1 and 2 EN tumors express high levels of the alveolar cell marker k-casein, but low levels of the ductal cell marker NKCC1 (also known as ''solute carrier family 12, member 2'') ( Figure S4A ), suggesting an alveolar cellular origin. In contrast, MMTV-Wnt1 tumors do not express (or express low levels of) k-casein but express NKCC1 in a fraction of tumor cells, consistent with MaSCs as potential target cells to give rise to both ductal and/or alveolar cells (Li and Rosen, 2005) (Figure S4B ). Taken together, we conclude that target cells of mammary tumors arising in WCEN females are either committed bipotent alveolar progenitors (type 1) or luminal alveolar progenitors (type 2). These progenitors are within the transient Wap + cells in nulliparous females.
Wap-Cre;EN Mammary Tumors Express Both Luminal and Basal Gene Clusters
We compared EN tumors to other murine breast cancer models by microarray expression profiling, using hierarchical clustering based on an intrinsic gene list developed for murine models of breast cancer (Herschkowitz et al., 2007) . As shown in Figure 4C and Figure S5 , in general, compared to other murine models, EN tumors are relatively homogeneous and cluster together. However, the 3 type 2 tumors (D14T1, D14T2, and C117T1) form their own subcluster and are separated from the type 1 tumors. In contrast, tumors from parous (CR115, CR90-1, D14T1, and D14T2) and nulliparous (the remaining samples) females are mixed together and do not form distinct subclusters. These data suggest that the initiating oncogenic event and cellular origin, but not the reproductive history, are more important in determining phenotypes of EN tumors.
All type 1 EN tumors express 3 gene clusters, including a K5 basal gene cluster, a strong K14 cluster, and a strong Xbp1 luminal gene cluster, similar to MMTV-Wnt1 tumors ( Figure 4C ). Type 2 EN tumors express the K14 and Xbp1 clusters, but not the K5 cluster. In contrast, tumors from both MMTV-Neu and MMTV-PyVT mice only express the Xbp1 luminal cluster ( Figure 4C ). Of note, MMTV-Wnt1 tumors are more heterogeneous than EN tumors and they can also be divided into two major subclusters. One contains K5 and K14 clusters, but not the Xbp1 luminal cluster ( Figure 4C , cluster I). The other contains the K5 basal cluster and the Xbp1 luminal cluster (though expressed at slightly lower levels), but not the K14 cluster ( Figure 4C , cluster II). These differences may be due in part to their different cells of origin, with MaSCs as more likely targets of MMTV-Wnt1 tumors, and committed progenitors as targets of EN.
An AP1 Signature Associated with EN-Mediated Mammary Tumorigenesis
To understand the mechanism of EN-mediated mammary tumorigenesis, we first performed GSEA on microarray expression profiles from unsorted EN tumors compared to those from normal MGs, using curated gene sets (c2 collection) for metabolic and signaling pathways from the GSEA molecular signature database website (http:// www.broad.mit.edu/gsea/msigdb/msigdb_index.html). Unexpectedly, this analysis only revealed pathways that seem to be common for tumor cells in general (e.g., reflecting increased metabolic activities and proliferation; Table S1 ). Two possibilities may account for this result. First, pathways that are active in both normal MGs and tumors may not be revealed by this assay. Second, noncancerous cells in these tumors could introduce significant ''noise'' in unsorted tumor samples.
In our WCENLZ animals, tumor epithelial cells are labeled by lacZ (Figures 3B-3E) . Thus, we have the opportunity to mark tumor epithelial cells and separate them from stromal cells. In addition, target cells of EN in WCLZ virgin females as well as premalignant, hyperplastic MECs in WCENLZ females are also marked by lacZ, thus providing an opportunity to isolate these cells for analysis.
We generated microarray expression profiles for several lacZ-sorted samples from either WCENLZ hyperplastic MGs that had not developed visible tumors, or mammary tumors that arose in WCENLZ females. We then compared sorted tumor cells to sorted hyperplastic MECs by GSEA using the above-described c2 gene sets, in an attempt to identify pathways upregulated during tumor progression. The top gene sets enriched in sorted tumor cells derived from this comparison are more informative than the comparison using unsorted tumors (Table S2 , compare to Table S1 ). Pathways related to the hypoxia response in tumors, WNT signaling, TRK/NGF signaling, TGFb signaling, and genes regulated by MYC are evident. To further validate the effectiveness of this approach, we also compared unsorted tumors to sorted hyperplastic MECs (thus both comparisons have the same baseline). The top gene sets enriched in unsorted tumors revealed from this analysis are very similar to those compared to normal MGs (Table S3, compare to Table S1 ), suggesting that GSEA using sorted tumor cells may reveal pathways with better specificity than using unsorted tumors.
We next compared sorted tumor cells to unsorted tumors by GSEA using c2 gene sets. We reasoned that genes/pathways upregulated specifically in tumor epithelial cells would be further enriched in this comparison. This would also potentially reveal an overall EN ''signature'' in the tumor epithelial cell compartment composed of pathways upregulated during the initial transformation, or tumor progression, or both. Among gene sets enriched in sorted tumor cells, we observed pathways related to genes regulated by C/EBP, IL6 response, HOXA5 targets, WNT signaling, JNK signaling, and TGFb signaling (Table S4) .
To determine what portion of the EN tumor signature is acquired during tumor initiation, ideally we would need to sort normal target cells of EN and compare their expression profiles to those from sorted hyperplastic MECs. Unfortunately, lacZ staining of mammary tissues by FDG dye yields a significant amount of background staining ($1%-3% even for lacZ À tissues). This background staining does not cause difficulty when sorting lacZ + hyperplastic MECs or tumor cells, which typically constitute $10%-40% of total cells, but prohibits sorting the small population of transient EN target cells (0.8%-4% as estimated by Wagner et al. ) with sufficient confidence. To overcome this technical limitation, we turned to an in vitro model of EN signaling. Because EN is a unique oncoprotein in that it transforms cells of all germ layers, we reasoned that the mechanism of ENmediated transformation might be conserved in different cell types. EN-mediated signaling in NIH 3T3 cells has been studied previously (Tognon et al., 2001; Wai et al., 2000) , many of which were also observed in EN tumors ( Figure 2D ). Thus, we generated microarray expression profiles from EN-transduced 3T3 cells (EN-3T3) and compared them to those of untransformed 3T3 cells. By performing GSEA using c2 gene sets, we identified several common gene sets that are enriched in both EN-3T3 cells and sorted EN tumor cells, including 2 IL6 pathways, ''WNT_TARGETS,'' ''CHEN_HOXA5_TARGETS_UP,'' and ''TGF_BETA_SIGNALING_PATHWAY'' (Table S5 , compare to Table S4 ). Since ''WNT_TARGETS'' arose among the top-enriched gene sets in all three analyses, we next focused on this gene set. By comparing the core enrichment genes from all three analyses, we observed striking similarity between sorted tumor cells (compared to unsorted tumors) and EN-3T3 cells (compared to control 3T3 cells) ( Figures S6A and  S6B) , including genes such as JUN, FOSL1, PLAUR, and CD44. JUN and FOSL1 (also known as FRA1) encode components of the AP1 complex and are target genes of b-catenin in human colorectal carcinomas. PLAUR encodes uPAR, and its transcription is activated through AP1 (Mann et al., 1999) . In addition, CD44 can also be upregulated by AP1 activity (Lamb et al., 1997) . Thus, this four-gene set appears to represent an AP1 signature. Consistent with the above data, we also observed enrichment of all gene sets containing genes with the AP1-binding motif in the c3 collection of GSEA database in sorted tumor cells and EN-3T3 cells (Table S6 ). More directly, we manually compiled a gene set for AP1 target genes based on published literature (plus JUN and FOSL1) (Eferl and Wagner, 2003) and observed its significant enrichment in both sorted EN tumor cells and EN-3T3 cells ( Figures 5A and 5B ). In addition to the above-described four-gene set, we identified additional AP1 target genes that are upregulated in both comparisons, including HBEGF (heparin-binding EGF-like growth factor), BCL2L11 (BIM), CDKN1A (p21), and CDKN2A (p16). p16 INK4A and p21 WAF1 typically function as tumor suppressors. However, both may also act as oncogenes. In fact, overexpression of p16 is found in breast cancer cases with a more malignant phenotype (Milde-Langosch et al., 2001) . Of note, we did not observe significant enrichment of this AP1 signature in sorted EN tumor cells compared to sorted EN hyperplastic MECs ( Figure 5C and Figure S6C ), suggesting that at least part of this signature might have already been acquired in hyperplastic MECs during the initial stage of EN transformation.
To confirm involvement of the c-Jun/Fosl1 AP1 complex in EN-mediated transformation, we performed electrophoretic mobility shift assays (EMSAs) on nuclear lysates from 3T3 cells and observed a significantly larger and specific band shift created by AP1 complex formation in EN-3T3 cells ( Figure 6A ). This AP1 complex was composed of c-Jun and Fosl1 or Fosl2 ( Figure 6B ). Western blot analysis confirmed significantly elevated levels of total c-Jun, phosphorylated c-Jun, and Fosl1 only in EN-3T3 cells ( Figure 6C ), suggesting that c-Jun/Fosl1 is indeed the major AP1 complex formed upon EN-mediated transformation.
To validate upregulation and activation of the c-Jun/ Fosl1 complex in EN tumors, we performed immunostaining using antibodies against Fosl1, phosphorylated c-Jun, and total c-Jun. In WT MGs, Fosl1 is mainly localized in cytoplasm (Figure 6Da ). In EN hyperplastic MECs and tumor cells, the overall intensity of Fosl1 staining is increased, and more importantly, significant Fosl1 nuclear staining is detected (Figures 6Db and 6Dc) . In addition, upregulation and phosphorylation of c-Jun is also evident in EN hyperplastic MECs and tumor cells, but not in WT MGs (Figures 6Dd-6Dl) , suggesting that activation of this AP1 complex is an early event (i.e., present in hyperplastic MECs) and persists in EN-mediated tumorigenesis.
To determine the c-Jun/Fosl1 status in human SBC, we stained three SBC cases with c-JUN and FOSL1 antibodies. As shown in Figure 6E , in three of three SBC samples studied, we detected nuclear staining of FOSL1, and expression and activation (phosphorylation) of c-JUN, suggesting that activation of the c-JUN/FOSL1 complex is indeed associated with human SBC.
Expression of a Dominant-Negative c-Jun Blocks EN-Mediated Transformation
To determine if AP1 activation is necessary for EN-mediated transformation, we employed the dominant-negative (DN) c-Jun TAM67, which lacks its transactivation domain, to block the AP1 activity (Ludes-Meyers et al., 2001) in several different systems. Coexpression of DN c-Jun in EN-3T3 cells blocked EN-mediated transformation both morphologically and molecularly ( Figures 7A-7D ). Ectopic expression of EN in the murine EpH4 cells and human MCF10A cells led to larger spheroids in 3D Matrigel cultures, which was reverted by coexpression of DN c-Jun ( Figures 7E  and 7F ). We have shown previously that EN-transduced EpH4 (EN-EpH4) cells formed tumors upon subcutaneous injection in immunodeficient mice (Tognon et al., 2002) . We now show that expression of DN c-Jun in EN-EpH4 cells significantly reduces their tumorigenic properties in vivo ( Figures 7G and 7H) . We compared microarray expression profiles between EN-EpH4 tumors and DN c-Jun/EN-EpH4 tumors by GSEA. As expected, many gene sets enriched in sorted EN tumor cells (compared to unsorted EN tumors) are downregulated in DN c-Jun/EN-EpH4 tumors (Table  S7) . Importantly, one of them is ''JNK_UP,'' a gene set directly related to JNK-JUN signaling.
Lastly Figure 7I) . Intriguingly, the Gfp hi population was significantly smaller than the other two. In contrast, the majority of tumor cells in the control (LPIG) tumor were Gfp + cells expressing high levels of Gfp. We individually sorted these distinct populations of Gfp + cells and confirmed they were all derived from virally transduced cells ( Figure 7J ). We then quantitated DN cJun expression levels and compared these to virally transduced cells before transplantation (i.e., input). Consistent with their Gfp expression levels, the Gfp hi , Gfp mid , and Gfp low cells in the DN c-Jun-transduced tumor also expressed high, medium, and low levels of DN c-Jun, respectively. In addition, even the Gfp hi tumor cells expressed much lower levels of DN c-Jun than those of the input ( Figure 7K ). These findings suggest that selection against EN tumor cells expressing high levels of DN c-Jun occurs in vivo. Upon staining with antibodies for stem/progenitor markers CD61 and CD49f, we found the DN c-Jun-transduced tumors contained fewer CD61 + CD49f + cells than the control tumors ( Figure 7L ). 
DISCUSSION Committed Mammary Progenitors as Cells of Origin for Breast Cancer
A central question in cancer biology is the cellular origin of cancers. Do cancers originate from normal stem cells that lose normal growth control, or do they initiate from progenitors or more differentiated cells after acquisition of stem cell attributes through mutation(s) (Lobo et al., 2007) ? Current views are derived largely from studies of leukemias in the hematopoietic system. Since hematopoietic stem cells (HSCs) are endowed with self-renewal, it has been argued that transformation of HSCs provides a simple means to generate leukemic cells. Paradoxically, cellular phenotypes in diverse leukemias mirror those of progenitors, rather than HSCs (Lobo et al., 2007) . In fact, evidence in both patients and mouse models favors a progenitor cell origin for many leukemias (e.g., see Jamieson et al., 2004; Krivtsov et al., 2006) . Similarly, although MaSCs are often proposed as cells of origin for breast tumors, cellular phenotypes of human breast cancer are not easily reconciled with this view. For instance, since MaSCs can give rise to both luminal and myoepithelial cells, one would expect to see mixed cell types in breast cancer if MaSCs represent the predominant cellular origin, yet most human breast tumors exhibit phenotypes of luminal epithelial cells (Sorlie et al., 2001 ). This suggests that more differentiated cells in MGs may serve as cells of origin for breast cancer. However, the existence of such committed progenitors in normal MGs remains to be directly demonstrated. Likewise, direct evidence is also lacking to show such cells as targets of transformation leading to breast cancer.
The cellular origin of human breast cancer is difficult to establish. Murine models, therefore, represent a tractable alternative for analysis. Previous studies using murine models have proposed both MaSCs and more differentiated cells, including mammary progenitors, as targets of breast cancer (Li and Rosen, 2005) . Moreover, in murine models created by overexpression of oncogenes driven by the same promoter (e.g., MMTV), different oncogenes (e.g., Wnt1/b-catenin versus Neu or H-Ras or PyMT) appear to preferentially transform distinct populations of MECs. However, due to use of exogenous promoters (thus oncogenes often expressed at nonphysiological levels), and in the absence of genetic marking and thorough characterization of tumor cell types, these models cannot definitively assign target cells within the normal MEC developmental hierarchy.
In WCEN mice, EN is under the transcriptional control of the endogenous Etv6 promoter and therefore should be expressed at a physiological level. Previous studies using genetic marking have identified a population of multipotent MECs (termed parity-induced MECs, or PI-MECs) that originate from Wap-Cre-expressing differentiating cells during the first pregnancy/lactating cycle, survive through postlactational remodeling, and persist throughout the remainder of life (Boulanger et al., 2005; Henry et al., 2004; Wagner et al., 2002; Wagner and Smith, 2005) . Recently, a population of alveolar progenitor cells, similar to PI-MECs, was identified in nulliparous mouse MGs (Booth et al., 2007) . These cells represent lobule-restricted multipotent progenitors capable of proliferation and differentiation to both luminal and myoepithelial cells upon transplantation. Apparently, these progenitor cells are targets of EN in WCEN virgin females, as described in this study.
Our study also supports the existence of an epithelial cell hierarchy in both normal MGs and in mammary tumors. We have described at least two types of committed alveolar progenitors in the transient population Figure 4B , this study) or K14 + K18 + luminal cells is also detected . In addition, our microarray analysis of murine breast cancer models also shows that the K14 gene cluster is distinct from the K5 basal gene cluster ( Figure 4C ; also Herschkowitz et al., 2007) . Thus, K14 is distinct from K5 as a marker, and a combination of both markers together with other markers (e.g., p63, SMA, K8) can be used to define subpopulations of cells in murine mammary tumors.
Although we show that EN transforms committed alveolar progenitors, we do not dismiss the possibility that EN may also transform MaSCs. Interestingly, as we described above, due to the leaky expression of the EN allele (without Cre-mediated excision of the ''stopper,'' thus independent of the Wap promoter), a small number of EN-only heterozygous mice develop mammary tumors at advanced ages. Most of these tumors fall within one of the four subtypes described above in WCEN females ( Figure S7 ), suggesting that target cells of EN in these two types of mice are probably similar. However, under this genetic setting, one cannot be certain if bipotent tumors with type 1 features are derived from committed bipotent progenitors (similar to WCEN) or from MaSCs, since they probably give rise to tumors with a similar appearance. In addition to tumors with features of these four subtypes, we also observed tumors either containing extensively K5 + basal cells, or containing mainly K8 + (but K14 À ) luminal cells ( Figure S7 ). This is most likely due to the long latency of tumors that develop in EN-only mice (>1 year compared to several months for WCEN females). More differentiated, single lineage-committed cells may be transformed by EN after they accumulate additional mutations over an extended time period.
Transformation by EN Oncoprotein Is Mediated through the AP1 Complex
The AP1 transcriptional complex is composed of heterodimeric Jun/Fos family proteins (Eferl and Wagner, 2003) . The AP1 pathway integrates multiple growth signals at the transcriptional level and regulates several cellular processes (Shen et al., 2007) . In normal MGs, previous studies have shown that AP1 is a pivotal regulator of postnatal MG growth and development (Shen et al., 2006) . In human breast cancer, c-JUN activation is associated with proliferation and angiogenesis in invasive breast cancer (Vleugel et al., 2006) . Overexpression of the DN c-Jun in breast cancer cells induces a G1 cell cycle block and inhibits their growth both in vitro and in vivo (Liu et al., 2002) . Fosl1 (Fra1) regulates proliferation and invasiveness of breast cancer cells (Belguise et al., 2005; Milde-Langosch et al., 2004) . Overexpression of FOSL1 (FRA-I) protein has been observed in both hyperplastic and neoplastic human breast disorders (Chiappetta et al., 2007) . In addition, Fosl1 was also used as an effective target for a DNA vaccine to protect mice against breast cancer (Luo et al., 2003) . Our findings demonstrate that EN expression leads to upregulation and activation of the c-Jun/Fosl1 AP1 complex. Several AP1 target genes are upregulated in both EN-3T3 cells and EN tumor cells ( Figures 5A and 5B and Figures S6A and S6B) , including HBEGF and possibly CCND1 (cyclin D1), which stimulate proliferation. Cyclin D1 is the major positive regulator of cell cycle progression induced by AP1 (Bakiri et al., 2000) . Although we did not observe increased levels of cyclin D1 in sorted tumor cells directly compared to unsorted tumors (possibly due to its expression in stromal cells), we observed its upregulation in EN-3T3 cells both by microarray and western blot (Figures 2D and 5B). We demonstrated its upregulation during tumor progression ( Figure 5C ). We also detected high levels of cyclin D1/2 expression in EN tumors by western blot ( Figure 2D ). Intriguingly, our microarray analysis shows that several AP1 target genes known to promote angiogenesis and invasiveness, including PLAUR, PLAU, CD44, CTSL (cathepsin L), MMP3 (matrix metallopeptidase 3), and TPM3 (tropomyosin 3) are upregulated in both EN-3T3 cells and EN hyperplastic MECs ( Figures 5B and 5C ), suggesting that an EN/AP1-induced invasiveness program may be established early in EN-mediated transformation. This observation may partially account for the short latency and aggressiveness of EN tumors in mice, and the appearance of SBC in children as young as 3 years of age (Euhus et al., 2002) .
Together with previous observations in human breast cancer cells, our study supports critical roles of AP1 in breast tumorigenesis and invasiveness. Further focus on this transcriptional complex as a target in human breast cancer is warranted.
Modeling Chromosomal Rearrangements in Human Epithelial Tumors Can Provide Insights into Their Pathogenesis and Therapy
The breast cancer model described here is based on the t(12;15)(p13;q25) translocation in human cancer. Our data demonstrate that the translocation-generated EN fusion oncoprotein is sufficient to initiate mammary tumorigenesis. This complements genetic evidence in humans suggesting that this translocation is the primary event in the disorder (Tognon et al., 2002 ). In our model, EN is induced only in a very small number of cells in mammary tissues and the tumor cells emerge within the environment of normal cells, thus closely mimicking human disease initiated by somatic mutation. The recent findings of recurrent gene fusions in prostate cancer and lung cancer suggest that balanced, disease-specific chromosomal rearrangements in epithelial cancers may be more common and important than previously believed (Meyerson, 2007; Tomlins et al., 2005) . As demonstrated in hematopoietic malignancies, study of gene rearrangements has contributed immeasurably to an understanding of both normal blood cell development and malignancy. In addition, study of gene fusions with kinase activities has revolutionized targeted therapies for cancer (e.g., imatinib for BCR-ABL fusion). We hope that the success in modeling an infrequent translocation seen in human epithelial cancer described here will inspire the generation of sophisticated models of other chromosomal arrangements that may occur more commonly in other epithelial tumors. Such engineered mice permit experimental access to the earliest target cells and steps in the transformation process and may serve as effective models for preclinical testing.
EXPERIMENTAL PROCEDURES Mice
Etv6-NTRK3 conditional knockin mice were generated by gene targeting (details are provided in the Supplemental Experimental Procedures). Biochemical and Cellular Assays Standard protocols were followed. Details about EMSAs, western blot, immunoprecipitation studies, and soft agar assays are provided in the Supplemental Experimental Procedures.
Microarray Data Collection and Analysis
Microarray expression profiles were collected using Affymetrix or Agilent chips and analyzed using dChip (Li and Wong, 2001 ) and GSEA (Subramanian et al., 2005) as described. Details are provided in the Supplemental Experimental Procedures. All microarray data have been deposited in NCBI's Gene Expression Omnibus (GEO; http:// www.ncbi.nlm.nih.gov/geo/) with GEO Series accession numbers GSE9355 (EN tumors using Affymetrix chips), GSE9354 (3T3 cells), GSE9353 (EpH4-derived tumors), and GSE9343 (selected EN tumors using Agilent chips).
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures, seven supplemental figures, and eight supplemental tables and can be found with this article online at http://www.cancercell.org/cgi/ content/full/12/6/542/DC1/. 
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